Tuesday, July 23, 2024
HomeLatest Pharma-NewsEU approval IdefirixTM in highly sensitized kidney transplant patients

EU approval IdefirixTM in highly sensitized kidney transplant patients

August 26, 2020: “Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases announced that the European Commission has granted conditional approval for IdefirixTM in highly sensitized kidney transplants patients.

The formal approval by the European Commission was received two months after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending conditional approval of Idefirix for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.

- Advertisement -

“We are very excited about today’s decision from the European Commision to approve Idefirix in highly sensitized kidney transplant patients.

This is the first approved drug for Hansa Biopharma and will bring hope to the thousands of highly sensitized patients across Europe waiting for a life-saving kidney transplant” says Søren Tulstrup, President & CEO of Hansa Biopharma.

“Today’s approval further serves as a validation of the potential of Hansa Biopharma’s proprietary drug development engine and will transform the company into a commercial stage biopharmaceutical company that brings lifesaving and life altering therapies to patients with rare diseases who need them and generate value to society at large.” 

Idefirix has been reviewed as part of the European Medicines Agency’s (EMA) PRIority MEdicines (PRIME) programs, which support medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options.

The first treatments with Idefirix is expected to be available to patients in select European countries during the fourth quarter 2020, as communicated earlier.” 


Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular